| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Anxiolytic-like effect of the selective neuropeptide Y Y2 receptor antagonist BIIE0246 in the elevated plus-maze.
|
Peptides
|
2006
|
1.03
|
|
2
|
Different susceptibility to social defeat stress of BalbC and C57BL6/J mice.
|
Behav Brain Res
|
2010
|
0.97
|
|
3
|
SB-649915-B, a novel 5-HT1A/B autoreceptor antagonist and serotonin reuptake inhibitor, is anxiolytic and displays fast onset activity in the rat high light social interaction test.
|
Neuropsychopharmacology
|
2007
|
0.93
|
|
4
|
Expression analysis of brain-derived neurotrophic factor (BDNF) mRNA isoforms after chronic and acute antidepressant treatment.
|
Brain Res
|
2004
|
0.91
|
|
5
|
Social defeat-induced contextual conditioning differentially imprints behavioral and adrenal reactivity: a time-course study in the rat.
|
Physiol Behav
|
2007
|
0.89
|
|
6
|
Strain-specific outcomes of repeated social defeat and chronic fluoxetine treatment in the mouse.
|
Pharmacol Biochem Behav
|
2010
|
0.89
|
|
7
|
CRF1 receptor activation increases the response of neurons in the basolateral nucleus of the amygdala to afferent stimulation.
|
Front Behav Neurosci
|
2008
|
0.86
|
|
8
|
Selectivity of d[Cha4]AVP and SSR149415 at human vasopressin and oxytocin receptors: evidence that SSR149415 is a mixed vasopressin V1b/oxytocin receptor antagonist.
|
Br J Pharmacol
|
2005
|
0.86
|
|
9
|
Transient forebrain over-expression of CRF induces plasma corticosterone and mild behavioural changes in adult conditional CRF transgenic mice.
|
Pharmacol Biochem Behav
|
2009
|
0.86
|
|
10
|
Synthesis and pharmacological characterization of novel druglike corticotropin-releasing factor 1 antagonists.
|
J Med Chem
|
2008
|
0.85
|
|
11
|
Alterations of behavioral and endocrinological reactivity induced by 3 brief social defeats in rats: relevance to human psychopathology.
|
Psychoneuroendocrinology
|
2009
|
0.84
|
|
12
|
Characterisation of the selective 5-HT1B receptor antagonist SB-616234-A (1-[6-(cis-3,5-dimethylpiperazin-1-yl)-2,3-dihydro-5-methoxyindol-1-yl]-1-[2'-methyl-4'-(5-methyl-1,2,4-oxadiazol-3-yl)biphenyl-4-yl]methanone hydrochloride): in vivo neurochemical and behavioural evidence of anxiolytic/antidepressant activity.
|
Neuropharmacology
|
2006
|
0.83
|
|
13
|
Single exposure to social defeat increases corticotropin-releasing factor and glucocorticoid receptor mRNA expression in rat hippocampus.
|
Brain Res
|
2005
|
0.83
|
|
14
|
6-(3,4-dichlorophenyl)-1-[(methyloxy)methyl]-3-azabicyclo[4.1.0]heptane: a new potent and selective triple reuptake inhibitor.
|
J Med Chem
|
2010
|
0.80
|
|
15
|
Conditioning properties of social subordination in rats: behavioral and biochemical correlates of anxiety.
|
Horm Behav
|
2006
|
0.79
|
|
16
|
Effects of antidepressant drugs and GR 205171, an neurokinin-1 (NK1) receptor antagonist, on the response in the forced swim test and on monoamine extracellular levels in the frontal cortex of the mouse.
|
Neurosci Lett
|
2003
|
0.79
|
|
17
|
Regional changes in the contralateral "healthy" hemisphere after ischemic lesions evaluated by quantitative T2 parametric maps.
|
Anat Rec
|
2002
|
0.78
|
|
18
|
1-(Aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes and 6-(aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes: a new series of potent and selective triple reuptake inhibitors.
|
J Med Chem
|
2010
|
0.78
|
|
19
|
Dihydropyrrole[2,3-d]pyridine derivatives as novel corticotropin-releasing factor-1 antagonists: mapping of the receptor binding pocket by in silico docking studies.
|
J Med Chem
|
2008
|
0.77
|
|
20
|
Distinct receptor subtypes mediate arginine vasopressin-dependent ACTH release and intracellular calcium mobilization in rat pituitary cells.
|
Eur J Pharmacol
|
2012
|
0.77
|
|
21
|
Effect of the p38 MAPK inhibitor SB-239063 on Lipopolysaccharide-induced psychomotor retardation and peripheral biomarker alterations in rats.
|
Eur J Pharmacol
|
2011
|
0.77
|
|
22
|
Heteroaryl-substituted 4-(1H-pyrazol-1-yl)-5,6-dihydro-1H-pyrrolo[2,3-d]pyrimidine derivatives as potent and selective corticotropin-releasing factor receptor-1 antagonists.
|
ChemMedChem
|
2008
|
0.76
|
|
23
|
5-{2-[4-(2-methyl-5-quinolinyl)-1-piperazinyl]ethyl}-2(1H)-quinolinones and 3,4-dihydro-2(1H)-quinolinones: dual-acting 5-HT1 receptor antagonists and serotonin reuptake inhibitors. Part 3.
|
Bioorg Med Chem Lett
|
2010
|
0.75
|
|
24
|
Enantiomerically pure tetrahydroquinoline derivatives as in vivo potent antagonists of the glycine binding site associated to the NMDA receptor.
|
Bioorg Med Chem Lett
|
2003
|
0.75
|
|
25
|
The characterization of a novel V1b antagonist lead series.
|
Bioorg Med Chem Lett
|
2010
|
0.75
|
|
26
|
Design and synthesis of novel tricyclic benzoxazines as potent 5-HT(1A/B/D) receptor antagonists leading to the discovery of 6-{2-[4-(2-methyl-5-quinolinyl)-1-piperazinyl]ethyl}-4H-imidazo[5,1-c][1,4]benzoxazine-3-carboxamide (GSK588045).
|
J Med Chem
|
2010
|
0.75
|